Earlier this year, the biotech company featured in today’s article was a penny stock. But after uplisting to the Nasdaq, the author of today’s article notes that “it has been making big moves in the market and moving some of Wall Street’s top analysts to set initial targets over $20 right now.” For more on how this company’s approach to…
“In a world where interest rates are so low and uncertainty seems to be the norm, baby boomers need to look for stable dividend stocks that can compete with the current income of longer-term Treasury notes “Favorable government regulations, coupled with the introduction of new and sophisticated products, and growing demand for synthetic biology, should keep driving the biotech industry’s…
The author of today’s article advises that “before investing in a biotech company, it’s essential to look at the financial opportunity offered by its current lineup of products (or most promising pipeline candidates), both in the short and long run.” With that, they proceed to highlight two biotech stocks that could be top picks right now based on the great…
When it comes to the clinical-stage immunotherapy company discussed in today’s article, the author notes that “Despite being years away from making the jump from clinical to a commercial stage company, there have been numerous instances in the past several years of the stock seeing 100% or greater returns over periods of three months or less.” Given this, and with…
“Some of the market’s most rewarding opportunities can be found in small-cap stocks,” declares the author of today’s article – and with that, he proceeds to highlight three of the most popular small-cap stocks right now among Robinhood investors. For these three stocks – which include a veterinary health company with a medical device that could help it tap into…
While the biotech industry’s near-term potential is largely tied to the development of treatments for COVID-19, the author of today’s article notes that “The sector’s long-term potential remains solid due to the aging population and the rising cost of healthcare.” Against this backdrop, they proceed to highlight two biotech stocks that Wall Street analysts expect will see significant gains of…
At the mid-year point of 2021, what are the nation’s leading newsletter advisors’ favorite investment ideas for the remainder of the year? Today’s article reviews some of their top-performing picks from the beginning of the year and asks them for their mid-year updates. For ideas spanning biotech, cryptocurrency, electric vehicles, space exploration and more, CLICK HERE.
The author of today’s article’s favorite healthcare stock right now is a tech stock for the healthcare industry whose software is helping revolutionize the drug discovery process. More specifically, its solution “helps big pharma find the right molecule for the right target, and it helps them do it a lot quicker than normal human research” – and it’s being used…
While biotech companies are some of the largest disruptors in the broader healthcare sector, broad healthcare indexes tend to lack concentrated biotech exposure. As such, for investors choosing to follow an index strategy, the author of today’s article highlights two indexes that offer exposure to biotech stocks that have one or more drugs in Phase II and Phase III U.S.…
The price of Dogecoin – the current star of the cryptocurrency world – has fallen significantly from its recent highs. This has the author of today’s article advising that, “with the crypto bubble on shaky ground, aggressive investors might be wise to consider alternative growth vehicles soon” – and he highlights two biotech penny stocks to consider as those alternative…